Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease
about
Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In VivoNK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injurySubstance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in miceAn in vivo microdialysis study of FLZ penetration through the blood-brain barrier in normal and 6-hydroxydopamine induced Parkinson's disease model rats.Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidaseInvolvement of substance P and the NK-1 receptor in human pathology.Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: an in vitro and in vivo study.Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats.Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats.Antagonist of the neurokinin-1 receptor curbs neuroinflammation in ex vivo and in vitro models of Lyme neuroborreliosis.Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.Expression of substance P, neurokinin-1 receptor and immune markers in the brains of individuals with HIV-associated neuropathologyA survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.Neurodegeneration in Parkinson's disease: interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins.Neuropeptide substance P and the immune response.N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis.Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration.Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease.Functional single-walled carbon nanotubes 'CAR' for targeting dopamine delivery into the brain of parkinsonian mice.Mast cells in the brain - Old cells, new target.N-acetyl-L-tryptophan, a substance-P receptor antagonist attenuates aluminum-induced spatial memory deficit in rats.Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.Biochemical and Functional Changes in the Eye As a Manifestation of Systemic Degeneration of the Nervous System in ParkinsonismNeurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors
P2860
Q26798185-CECA169C-236F-499F-926F-F700028E4CD3Q33654943-F8DC8F98-D63C-4969-B7E4-FF2FF19297BEQ33778623-9FD66A36-6951-480E-9B7A-3EAB619A570BQ33876743-BBFBEB54-A8D3-4EB8-8552-51E9277C90DDQ34162782-75336994-31EC-4E6B-B25D-FA39C4B72292Q34413850-AF010B3B-A4D9-4B9F-BF23-0F0D9CD948E0Q34970674-D208F257-C130-4897-8395-EDE9F564B453Q35410165-E0CBF098-D0D5-437D-81D2-1AA3AC270407Q35619338-418BF8AA-C835-442F-A90D-9BD5EDB9142AQ35928366-0E4FC479-E7F5-46B5-A146-DE7AFD255086Q36416842-E1250304-6312-480A-8469-CF2931920E35Q36925594-49951112-781C-45EE-955F-4CADD95F0E1AQ37002601-2D591EA2-86EE-4A86-8083-984A9C9C8BCAQ37302953-2B057CD9-3958-4D02-88B7-030A89F0A6CAQ38111109-02890C10-301A-4275-87B6-F241E61DC889Q38148491-0ABED81F-3849-4CD9-A7B9-6AD8C02EFFC3Q38868323-EEC59670-7309-40C8-93EE-C580F9814C96Q38868878-B12447F8-9D36-4524-A5B3-BCE39614FD71Q38949089-E5B2FA7C-0946-4CEC-8035-BF3AFC22B781Q41097407-F066C28C-7988-472C-9E27-49C7293A3715Q43197155-EA6175FB-DBEB-4DB1-93D6-ABF406DB05E4Q46333318-FDC45714-ABAF-49A8-BC78-AD5D7E152572Q47712486-2BED12FB-63C8-47C9-B5F8-3DD4A301BAA3Q47777443-09508AF8-993F-4DF9-A9B5-BD3BD5F3CA09Q53059036-96F27396-D274-44C5-B8C8-FCB4D8050A0BQ58568981-58B4A1F0-CA6D-44FC-A32A-79CF44B41057Q58694067-18225955-E74E-43E0-9AED-AD6C938EACCD
P2860
Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Treatment with a substance P r ...... l of early Parkinson's disease
@ast
Treatment with a substance P r ...... l of early Parkinson's disease
@en
Treatment with a substance P r ...... l of early Parkinson's disease
@nl
type
label
Treatment with a substance P r ...... l of early Parkinson's disease
@ast
Treatment with a substance P r ...... l of early Parkinson's disease
@en
Treatment with a substance P r ...... l of early Parkinson's disease
@nl
prefLabel
Treatment with a substance P r ...... l of early Parkinson's disease
@ast
Treatment with a substance P r ...... l of early Parkinson's disease
@en
Treatment with a substance P r ...... l of early Parkinson's disease
@nl
P2860
P1433
P1476
Treatment with a substance P r ...... l of early Parkinson's disease
@en
P2093
Emma Thornton
Robert Vink
P2860
P304
P356
10.1371/JOURNAL.PONE.0034138
P407
P577
2012-04-02T00:00:00Z